Treatment News : Lens Into Specific Antibody Evolution May Foresee HIV Vaccine

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 11, 2014

Lens Into Specific Antibody Evolution May Foresee HIV Vaccine

Researchers have mapped the development of a key antibody as well as its interplay with HIV over time, establishing scientific knowhow that may aid in the development of a vaccine. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID)—which is a division of the National Institutes of Health (NIH)—along with the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and other groups studied an antibody that targets a site known as V1V2 on the virus and published their findings in Nature.

V1V2 is rare in that it does not apparently change as the viral population mutates. Thus, if a vaccine could target this site, it would likely have success whereas an attempt to go after a site inclined to mutate would fail. Research has suggested that antibodies targeting V1V2 helped prevent the spread of HIV in the one vaccine trial that has thus far showed moderate success.

In this study, the researchers found an individual in the CAPRISA cohort who, severl months after contracting HIV, naturally developed a neutralizing antibody, called CAP256-VRC26, that targeted V1V2. The scientists charted the evolution of this antibody by analyzing samples taken between 15 weeks and four years after the volunteer was infected.

The researchers were able to determine the genetic makeup of the original antibody and then map the antibody as it mutated and became more potent and effective. They were also able to detail the interchange between the virus and the antibody and to understand how this interaction fueled the ultimate development of the antibody into a powerful anti-HIV agent.

They found that not much time was required for the antibody to evolve and become particularly potent. Consequently, a vaccine targeting V1V2 would be more likely to succeed because fewer steps would be required to get the antibody to evolve to the desired form. Researchers have already begun work on attempting to develop a vaccine that could both prompt the body to produce V1V2-centric neutralizing antibodies and coax them into maturing into an effective means of protecting against the virus.

To read the NIH release, click here.

To read the Nature abstract, click here.

Search: HIV, vaccine, antibody, National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health, NIH, Centre for the AIDS Programme of Research in South Africa, CAPRISA, V1V2, CAP256-VRC26.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.